{
    "pmcid": "9169858",
    "qa_pairs": {
        "What innovative method was developed in the study to screen for allosteric inhibitors of the SARS-CoV-2 main protease?": [
            "A NanoBiT-based high-throughput assay",
            "A fluorescence resonance energy transfer (FRET) assay",
            "An enzyme-linked immunosorbent assay (ELISA)",
            "A surface plasmon resonance (SPR) assay"
        ],
        "What is the binding affinity of nanobody NB2B4 to the SARS-CoV-2 main protease as measured by biolayer interferometry?": [
            "0.461 nM",
            "2.426 nM",
            "1.234 nM",
            "3.678 nM"
        ],
        "What is the primary role of nanobody NB2B4 in the study of SARS-CoV-2 main protease?": [
            "Stabilizing the extended conformation of Mpro, revealing potential allosteric targets.",
            "Acting as a competitive inhibitor by overlapping with the catalytic site.",
            "Stabilizing the compact conformation of Mpro, resembling the dimeric structure.",
            "Binding to the substrate binding site to block substrate access."
        ],
        "Which nanobody acts as both an allosteric and competitive inhibitor of the SARS-CoV-2 main protease?": [
            "NB1A2",
            "NB2B4",
            "NB3C1",
            "NB4D5"
        ],
        "Which structural domain does nanobody NB2B4 bind to in the SARS-CoV-2 main protease, causing significant rearrangements?": [
            "The \u03b1-helical domain",
            "The catalytic domain",
            "The substrate binding site",
            "The dimerization interface"
        ]
    }
}